DoD Multiple Sclerosis, Clinical Trial Award
ID: 353635Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353635
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Multiple Sclerosis Clinical Trial Award (MSRP CTA) to support innovative clinical trials aimed at improving the treatment and management of multiple sclerosis (MS). This grant opportunity invites applications for clinical trials that may range from small proof-of-concept studies to larger-scale trials, with funding levels set at $2 million for small trials (CTA-FL1) and up to $4 million for larger trials (CTA-FL2). The program emphasizes the importance of addressing the needs of military personnel and veterans, ensuring that proposed studies include diverse patient populations and demonstrate strong preliminary data. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, with an estimated total program funding of $8 million available for approximately three awards. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524MSRPCTA_GG.pdf
    The Department of Defense (DOD) is announcing the Fiscal Year 2024 Multiple Sclerosis Clinical Trial Award (MSRP CTA) under its Congressionally Directed Medical Research Programs. With a funding pool of $20 million, the program invites applications focused on innovative clinical trials that address multiple sclerosis (MS) treatment and management. The submission process includes a two-step requirement: a pre-application due by June 10, 2024, followed by an invited full application by October 7, 2024. Research proposals may explore two principal areas: promoting neuroprotection and repair in MS and treating MS symptoms through various interventions. Eligible applicants include both extramural and intramural organizations, with a principal investigator required to be an independent researcher. Projects can request funding between $2 million for small trials (CTA-FL1) and $4 million for larger trials (CTA-FL2). All proposals must demonstrate relevance to military personnel and veterans, ensuring access to diverse patient populations. The successful implementation of funded trials is expected to significantly impact MS research and patient care, reinforcing DOD's commitment to advancing medical research in service of the military community and the public.
    Similar Opportunities
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Exploration - Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Multiple Sclerosis Exploration - Hypothesis Development Award (MSRP EHDA), aimed at fostering innovative research in the field of multiple sclerosis (MS). This grant program supports high-risk, high-gain research concepts that challenge existing paradigms and lay the groundwork for future scientific investigations, with a focus on areas such as central nervous system repair and mechanisms contributing to MS etiology. The total estimated funding for this program is approximately $2 million, with an expected eight awards, and applications must follow a two-step submission process, including a pre-application due by June 10, 2024, and a full application due by October 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    CDMRP Neurofibromatosis Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Neurofibromatosis Clinical Trial Award to support innovative clinical trials aimed at addressing high-impact issues related to neurofibromatosis (NF), including NF1, NF2, and schwannomatosis. Applicants are required to present a clear clinical trial design, preliminary data, and access to suitable patient populations, with a focus on enhancing understanding, diagnosis, and treatment of NF to benefit service members, veterans, and the public. This funding opportunity, totaling approximately $1.6 million for the award, encourages collaborative proposals involving academia, industry, and military branches, with key deadlines for pre-applications on September 12, 2024, and full applications by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity titled "DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award" for Fiscal Year 2024. This funding initiative aims to support the rapid implementation of clinical trials that have the potential to significantly impact cancer treatment and management, particularly for military personnel and their families, addressing specific topic areas related to military health. With an estimated total program funding of $24 million and the expectation of awarding up to five grants, eligible applicants can submit proposals that demonstrate the feasibility and relevance of their clinical trials, with a maximum award amount of $3 million. Interested parties must submit their applications by October 15, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Peer Reviewed Orthopaedic, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 (FY24) Peer Reviewed Orthopaedic Clinical Trial Award aimed at enhancing recovery from combat-related orthopaedic injuries. This grant supports clinical trials that focus on innovative treatment strategies, including limb stabilization, battlefield care, and rehabilitation, with an emphasis on interdisciplinary collaboration to improve military readiness and patient care. With an estimated total program funding of $13.25 million, the program anticipates awarding up to four grants of $2.5 million each for standard projects and one grant of $3.25 million for collaborative care projects. Interested applicants must submit pre-applications by June 18, 2024, and full applications by September 17, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org.
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Psychedelic Treatment Research Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Psychedelic Treatment Research Clinical Trial Award (PTRCTA) to support clinical trials evaluating treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) among U.S. Service Members using specific psychedelic substances. Applicants are required to propose studies that address at least one of the covered conditions and utilize one or more of the eligible psychedelic substances, including MDMA, psilocybin, and ibogaine, with trials ranging from small proof-of-concept studies to larger efficacy trials. With an estimated total program funding of $9.8 million and the expectation of awarding two grants, interested parties must submit pre-applications by September 20, 2024, and full applications by October 4, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.